Autonomix Expands Its Patent Fortress as Precision Neuromodulation Emerges as a New Frontier in Cancer Care
Autonomix Medical (NASDAQ:AMIX) has strengthened its long-term position in precision medicine with the issuance of U.S. Patent No. 12,433,670, broadening intellectual property protection around its nerve sensing, mapping and targeted neuromodulation platform. While the company remains in the clinical development stage, the new patent reinforces a strategy centered on building a differentiated technology platform that could extend well beyond pain management into oncology, organ-function disorders and diseases of the autonomic nervous system.